Brief: Acer Therapeutics Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq
31/05/2022 21:16
May 31 (Reuters) - Acer Therapeutics Inc ACER.O :
* ACER THERAPEUTICS - ON MAY 31, CO RECEIVED NOTICE OF
DELISTING
OR FAILURE TO SATISFY CONTINUED LISTING RULE OR STANDARD FROM
NASDAQ - FILING
Further company coverage: ACER.O
Recent news on Acer Therapeutics
See all newsBrief: Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Acer Therapeutics Shareholders Vote "For" The Proposed Merger And Related Proposals
U.S. STOCKS ON THE MOVE-UGI, SkyWest, Sage Therapeutics
Acer Therapeutics surges on Zevra buyout deal
Brief: Zevra Therapeutics To Acquire Acer Therapeutics, Expanding Its Rare Disease Portfolio And Adding Commercial Product
Swiss stocks - Factors to watch on August 31